The patent challenges of 34 domestic companies for Boryung's Dukarb are following one after another.

It is analyzed that the expiration of the substance patent of Fimasartan is approaching two years in the future, and it is aiming for the early release of generics for combination drugs including Fimasartan. According to the pharmaceutical industry on the 19th, there are a total of 34 companies that have applied for a trial to confirm the scope of passive rights to Dukarb's complex composition patents until this day.

Companies that have additionally challenged for patents are ▲Navipharm ▲Dongkoo ▲Shin Poong ▲Kims Pharma ▲HLB ▲Futecs ▲Daehan New Pharm ▲Daewoong Bio ▲NBK ▲Youngil